within Pharmacolibrary.Drugs.ATC.M;

model M09AX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.0011,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Onasemnogene abeparvovec is a gene therapy used for the treatment of spinal muscular atrophy (SMA) in pediatric patients. It is an adeno-associated virus vector-based gene therapy delivering a functional copy of the human SMN1 gene. Approved for use in multiple jurisdictions including the US and EU.</p><h4>Pharmacokinetics</h4><p>No formal human pharmacokinetic model reported or characterized due to the drug being a gene therapy product; standard PK parameters such as systemic bioavailability, volume of distribution, or classical plasma clearance are not typically defined or measured for gene therapies. Existing publications and regulatory documents do not provide conventional pharmacokinetic parameters for onasemnogene abeparvovec.</p><h4>References</h4><ol><li>Gretchen Thomsen, Arthur H M Burghes, Caroline Hsieh, Janet Do, Binh T T Chu, Stephanie Perry, Basam Barkho, Petra Kaufmann, Douglas M Sproule, Douglas E Feltner, Wendy K Chung, Vicki L McGovern, Robert F Hevner, Miriam Conces, Christopher R Pierson, Mariacristina Scoto, Francesco Muntoni, Jerry R Mendell, Kevin D Foust,Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.,Nature medicine,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34608334/'>https://pubmed.ncbi.nlm.nih.gov/34608334/</a></li><li>Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Anna Kostera-Pruszczyk, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni,JEWELFISH: 24-month results from an open-label study in non-treatment-na√Øve patients with SMA receiving treatment with risdiplam.,Journal of neurology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/38733387/'>https://pubmed.ncbi.nlm.nih.gov/38733387/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M09AX09;
